Novo Nordisk and Microsoft jointly develop AI models to facilitate the discovery and development of new drugs

Novo Nordisk announced a new strategic partnership with Microsoft that combines Microsoft's computing services, cloud technology and artificial intelligence (AI) with Novo Nordisk's drug discovery, development and data science capabilities

In this collaboration, Microsoft will provide AI technologies, basic scientific models and expertise, and work with Novo Nordisk's data scientists and experts in early R&D to accelerate Novo Nordisk's drug discovery and development process

At present, Novo Nordisk and Microsoft have identified the first two application scenarios for the AI model they will jointly develop: the first application scenario is to use AI to automatically screen, summarize and analyze information from a large number of sources such as scientific literature, patents, reports, and discussion forums to help researchers obtain novel scientific insights; The application scenario of the second AI model aims to predict the risk of

"We are very excited about this collaboration, which allows us to work closely with Microsoft's top experts and expand our capabilities in digital science and AI," said Lars Fogh Iversen, Senior Vice President, Digital Science and Innovation at Novo Nordisk, "We are on the path to faster and larger adoption of AI in the field of drug discovery, which will lead to more groundbreaking creations with increased efficiency and ultimately better meeting patient needs.

"The partnership with Novo Nordisk provides an excellent opportunity for us to jointly promote AI itself to the highest level to date and apply it to enhance the creativity of human experts," said Vijay Mital, Vice President of AI Architecture and Strategy in Microsoft's Technology and Research Division

Source: